North America Hypertrophic and Keloid Scar Treatment Market Growth and Recent Trends by 2027

The hypertrophic and keloid scar treatment market in North America is expected to grow from US$ 1,972.60 million in 2020 to US$ 4,053.90 million by 2027; it is estimated to grow at a CAGR of 10.8% from 2020 to 2027.

The US, Canada, and Mexico are major economies in North America. Advantages of laser treatment is the major factor driving the growth of the North America hypertrophic and keloid scar treatment market. Technological advancements have led to the successful use of laser—especially 585 nm PDL, Q-switched 532 nm frequency-doubled Nd: YAG, and CO2 lasers, among other types—for treating hypertrophic and keloid scars. The laser treatment helps prevent scar formation after surgery; it reduces pain and itching and allows movement that is otherwise limited by the scar. The treatment is widely employed to treat hypertrophic and keloid scars caused by burns. According to the “Laser Management of Hypertrophic Burn Scars: a Comprehensive Review,” published in January 2020, burn-related injury follows more than 70% of hypertrophic scars. Similarly, according to the World Health Organization (WHO), burn is the major public health problem. Every year, ~265,000 deaths are registered due to scalds, electrical burns, and other burn forms. Moreover, 90% of the burn incidences are reported in low- and middle-income countries. As excessive collagen deposition leads to the generation of hypertrophic scars that lead to raised scars, laser treatment proves to be effective against them. Moreover, due to being a minimally invasive method, it ensures reduced scar thickness, pain, and postoperative recovery period. It also helps prevent the need for surgical excision and improves skin pigmentation, pliability, height, pruritus, texture, and heat sensitivity, among other skin conditions of the affected areas. Moreover, this treatment procedure proves to be cost-effective, especially for those opting for medical tourism. Owing to such advantages, there is high demand for the laser treatment curing hypertrophic and keloid scars, which is further anticipated to drive the market in North America.

North America is witnessing a growing number of COVID-19 cases; for instance, the number of cases increased to 400,549 with 12,857 deaths reported in the US. Additionally, Mexico and Canada cases are also growing. The global impacts of COVID-19 have affected several markets, including the hypertrophic and keloid scar treatment market. Although the healthcare sector has witnessed H1N1, SARS, and additional outbreaks in the last few years, the COVID-19 virus has made the situation more difficult due to its transmission mode. Since the outbreak of COVID-19, North America has been witnessing a growing number of COVID-19 cases. Several measures are being taken to restrain the disease and prevent transmission; nevertheless, the excessive number of COVID-19 cases has resulted in the cancellation of doctor's appointment and decreased demand for elective hypertrophic and keloid scar treatment to the long period of lockdown. In the US, due to the growing number of contaminated patients, healthcare practitioners and leading organizations are distracting the flow of health services from research and development to primary care, which slows down the process of innovation.

North America Hypertrophic and Keloid Scar Treatment Market Segmentation

North America Hypertrophic and Keloid Scar Treatment Market – By Scar Type

• Hypertrophic
• Keloid

North America Hypertrophic and Keloid Scar Treatment Market – By Product Type

• Injectables
• Topical
  • Gels
  • Silicone Sheets
  • Creams
  • Other
• Laser
  • CO2
  • Pulse-Dyed
  • Other
• Other

North America Hypertrophic and Keloid Scar Treatment Market – By End User

• Hospitals
• Clinics
• Homecare

North America Hypertrophic and Keloid Scar Treatment Market, by Country

• US
• Canada
• Mexico

North America Hypertrophic and Keloid Scar Treatment Market-Companies Mentioned

• Alliance Pharma PLC
• HRA Pharma
• Mölnlycke Health Care AB.
• Newmedical Technology Inc.
• Perrigo Company plc
• Rejûvaskin
• Smith & Nephew
• Sonoma Pharmaceuticals, Inc
• Suneva Medical

North America Hypertrophic and Keloid Scar Treatment Report Scope